Share ownership Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 12:30:50 2026-03-11 EDT			5-day change	1st Jan Change
121.24 ^CHF	-0.62%		-5.04%	+10.62%

03-10	Swiss stocks - Factors to watch on March 10	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE

Share class: Novartis AG

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	2,189,930,497	1,909,335,641 ( 87.19 %)	214,841,249 ( 9.81 %)	87.19 %

Major shareholders: Novartis AG

Name	Equities	%	Valuation
NOVARTIS AG 9.67 %	204,270,188	9.67 %	34 663 M CHF
Sandoz Family Foundation 2 %	42,248,437	2 %	7 169 M CHF
Sjunde AP-fonden 0.1601 %	3,382,210	0.1601 %	574 M CHF
State Street Global Advisors Ltd. 0.1493 %	3,153,293	0.1493 %	535 M CHF
DWS CH AG 0.1018 %	2,151,162	0.1018 %	365 M CHF
Nordea Investment Management AB 0.1004 %	2,121,103	0.1004 %	360 M CHF
Baloise Asset Management AG 0.0926 %	1,955,932	0.0926 %	332 M CHF
Basellandschaftliche Kantonalbank (Investment Management) 0.0793 %	1,675,602	0.0793 %	284 M CHF
Berner Kantonalbank AG (Investment Management) 0.0768 %	1,621,457	0.0768 %	275 M CHF
Banque Cantonale de Genève (Investment Management) 0.074 %	1,562,575	0.074 %	265 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Dodge & Cox 0.4267 %	9,014,641	0.4267 %	1 520 M CHF
Eaton Vance Management 0.4202 %	8,876,906	0.4202 %	1 497 M CHF
DFA Australia Ltd. 0.3778 %	7,980,227	0.3778 %	1 346 M CHF
PRIMECAP Management Co. 0.3588 %	7,579,274	0.3588 %	1 278 M CHF
Fisher Asset Management LLC 0.3534 %	7,465,850	0.3534 %	1 259 M CHF
Loomis, Sayles & Co. LP 0.262 %	5,534,215	0.262 %	933 M CHF
U.S. Trust Company of Delaware 0.2153 %	4,549,016	0.2153 %	767 M CHF
Fiduciary Trust Company International 0.212 %	4,479,307	0.212 %	755 M CHF
Wells Fargo Bank NA 0.1677 %	3,542,572	0.1677 %	597 M CHF
GQG Partners LLC 0.1495 %	3,158,122	0.1495 %	533 M CHF
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
LUKB Expert Fondsleitung AG -	123,244	-	21 M CHF
Fnb Stockbroking & Portfolio Management Pty Ltd. (Invt Mgmt) -	6,000	-	1 M CHF
Columbia Threadneedle Management Ltd. -	946	-	160 527 CHF
Melville Douglas Investment Management (Pty) Ltd. -	415	-	70 421 CHF

Breakdown by shareholder type

Novartis AG	9.67%
Institutional	8.24%
Other	2.95%
State Street Corp.	0.07%
Individuals	0.04%
SEI Investments Co.	0.03%
First Financial Bankshares, Inc.	0.01%
ABC arbitrage SA	0.01%
Unknown	78.98%

Based on 1000 largest holdings

Geographical origin of shareholders

Switzerland	12.84%
United States	5.64%
Australia	0.4%
United Kingdom	0.35%
Canada	0.33%
Sweden	0.27%
Germany	0.13%
Ireland	0.11%
Belgium	0.1%
Luxembourg	0.1%
France	0.1%
Netherlands	0.08%
Norway	0.07%
Liechtenstein	0.07%
Italy	0.06%
Spain	0.06%
New Zealand	0.05%
Denmark	0.05%
Finland	0.05%
Individuals	0.04%
Austria	0.04%
Japan	0.02%
South Africa	0.01%
Hong Kong	0.01%
Cyprus	0.01%

Based on 1000 largest holdings

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

04-28 - Earnings release - Q1 2026

More about the company